SRPT Walks The Talk, VSTM Grows, PULM Pulls Back, Smooth Sailing For VYGR

The following are some of the biotech stocks that made their way onto the Day’s Gainers & Losers’ list of September 6, 2017.


1. Verastem Inc. (VSTM)

Gained 28.13% to close Wednesday’s (Sep.6) trading at $4.92.

News: The Company has expanded its Duvelisib development program to include targeting the treatment of patients with Peripheral T-Cell Lymphoma. Duvelisib has also been granted Fast Track designation by the FDA for the treatment of patients with Peripheral T-Cell Lymphoma who have received at least one prior therapy.

Duvelisib is the Company’s lead drug candidate.

A phase III study of Duvelisib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma, dubbed DUO, is underway. Duvelisib’s potential is also being explored in patients with indolent non-Hodgkin lymphoma (iNHL) whose disease is refractory to rituximab and to either chemotherapy or radioimmunotherapy. The Company reported positive results from a phase II study of Duvelisib in patients with indolent non-Hodgkin lymphoma, dubbed DYNAMO, last June.

Near-term catalysts:

— Data from the DUO study are expected in the latter part of summer 2017.
— Initiation of a phase II study of Duvelisib in patients with relapsed or refractory PTCL is expected by year end.

2. Voyager Therapeutics Inc. (VYGR)

Gained 24.70% to close Wednesday’s trading at $13.63.

News: The Company announced positive results from its ongoing Phase 1b trial of VY-AADC01 in advanced Parkinson’s disease.

The study demonstrated durable, dose-dependent and time-dependent improvements across multiple measures of patients’ motor function after a one-time administration of VY-AADC01. These measures include patient-reported diaries, Parkinson’s disease rating scales, and activities of daily living.

Near-term catalysts:

— Initiation of pivotal phase 2-3 program of VY-AADC for advanced Parkinson’s disease expected during late 2017.
— Filing of an investigational new drug application for VY-SOD101 for the treatment of amyotrophic lateral sclerosis caused by mutations in the superoxide dismutase 1 gene during late 2017 or early 2018.

3. G1 Therapeutics Inc. (GTHX)

Gained 19.74% to close Wednesday’s trading at $25.72.

News: No news

The Company made its debut on the NASDAQ on May 17, 2017, offering its shares at a price of $15.00 each.

The Company has 3 drug candidates in its pipeline namely, Trilaciclib, G1T38 and G1T48.

Trilaciclib is under four Phase 2 clinical trials – three studies in patients with small-cell…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *